Completion of AffinityDNA Acquisition expanding global direct-to-consumer business
MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
Cancer
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million...
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland,...
Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel...
Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
Starton Therapeutics Reports Positive Results from Phase 1 Study Evaluating STAR-LLD, Continuous Delivery Lenalidomide
STAR-LLD well tolerated with no dose-related toxicity or adverse eventsSTAR LLD achieved 90% bioavailability across all dosesPlasma levels showed a...
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
RESEARCH TRIANGLE PARK, N.C., July 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
First Patient Enrolled in the Streamlined Localization (STREAMLoc) Registry Study Using SCOUT® at Biopsy in Canada
Prospective, observational study to assess the clinical utility of the SCOUT® Radar Localization System (SCOUT) in real-world practiceSOUTH JORDAN, Utah,...
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
∙ Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected...
CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma
CV8102 recommended dose identified; expansion trial to confirm safety, tolerability, and efficacy Trial expansion focuses on advanced melanoma, an indication of...
4 Ways Research and Treatment of Cancer are Changing Due to Blockchain Technology
Blockchain technology was originally designed to facilitate the safe transfer and storage of bitcoin, the world’s first and most popular...
Immunomedics In Software Project With Ideagen To Streamline Document Reviews Of Cancer Treatment Processes
Ideagen’s PleaseReview will improve review, co-authoring and redaction projects linked to cancer and other oncology treatments US-based pharmaceutical company, Immunomedics, is...